Tuesday, September 6, 2016

BRIEF-Allergan says egregious price hikes by "outlier" companies hurting venture capital investment

* Says Allergan aims to limit annual price increases of

branded therapeutic drugs to low to mid single digit percentage

range, slightly above current annual rate of inflation

* Says Allergan's planned price increase limits would be

similar to company's price increases seen in 2016, and should

follow in 2017, beyond

* Says Hillary Clinton's plan for oversight panels to monitor,

punish drugmakers that impose unreasonable price increases on

life-saving drugs impractical in free market system

Read more

No comments:

Post a Comment